A major candidate for the Covid-19 Corona virus vaccine, developed by the University of Oxford, has shown promising results in animal experiments and is expected to see massive production in India within months.
According to global reports, it is likely that the Serum Institute of India, the world’s largest vaccination institute in India this year, can produce up to 60 million doses.
The Serum Institute of India, according to the Chinese website “SCMP”, the world’s largest vaccine producer by volume, said this year it plans to produce up to 60 million doses of a possible vaccine developed by Oxford University, which is now undergoing human clinical trials in Britain.
The trend of the largest institute for sera to produce the vaccine krona virus
Adar Poonawala, CEO of Serum at Serology Institute, said that although the vaccine candidate, named “ChAdOx1 nCoV-19”, has not yet been proven to work against Covid-19, Serum decided to start its manufacture because it showed success in animal experiments and progressed To the tests on humans, where it was Inject 6 macaques with a vaccine filter At the Rocky Mountain Laboratory at the National Institutes of Health in Montana last month, according to the New York Times.
The newspaper reported, quoting researcher Vincent Munster, who conducted the test, that the animals were then exposed to large quantities of the new coronavirus, but all six remained healthy after more than 28 days.
“They are a group of highly qualified and great scholars (at Oxford) … so we said we would go with this and that is why we are confident,” Poonawala told Reuters in a telephone interview.
“Being a private limited company, not accountable to public investors or bankers, I can take on some risks and ignore some of the products and other commercial projects that I have planned at my current facility,” Poonawala said.
Poonawala said he hopes the Oxford vaccine trials, which are due to be completed around September, will succeed, while Oxford University scientists said last week that the primary focus of the initial tests is to ensure not only the success of the vaccine, but rather that it causes good immune responses and has no unacceptable side effects .
Serum, owned by Indian billionaire Cyrus Poonawala, is planning to manufacture the vaccine at its two factories in the western city of Pune, with the goal of producing up to 400 million doses next year if all goes well.
“The majority of the vaccine, at least initially, should go to our citizens before traveling abroad,” he said, adding that he would leave it up to the Indian government to decide which countries will receive the amount of the vaccine and when, adding that over the next five months, a serum will be spent between ($ 4.4M to $ 5.9M) making about 3-5 million doses per month.
The first recipient of the Oxford vaccine
Serum has partnered with American biotechnology company Codagenix and Austrian company Themis on other candidates for the Covid-19 vaccine, and plans to announce a fourth alliance within two weeks.
Poonawala said that the Serum board of directors had also agreed last week to invest approximately ($ 8.8 billion) in establishing a new manufacturing unit to produce only Corona virus vaccines.
Other vaccines worldwide
There are currently up to 100 potential Covid-19 vaccines currently under development by biotechnology and research teams around the world, at least 5 of which are in initial testing in people in so-called first stage clinical trials.
So far more than 3 million people have been infected worldwide, and more than 210,000 people have died from Covid-19, a respiratory disease caused by coronaviruses.